Allied Market Research reports that the global seborrheic dermatitis treatment market generated $2.3 billion in 2021 and is projected to reach $6.6 billion by 2031, with a CAGR of 11.0% from 2022 to 2031. The growth is driven by an increase in autoimmune diseases, technological advancements, and more treatment options. High treatment costs and the availability of home remedies pose challenges. The cream segment leads the market, while prescription-based drugs hold the largest share. North America currently dominates the market, but the Asia-Pacific region shows the fastest growth potential, with a CAGR of 12.0%.
Almirall, a global biopharmaceutical company focused on skin health, will participate in the 41st Annual J.P. Morgan Healthcare Conference in San Francisco from January 9-12, 2023. Carlos Gallardo, Chairman and CEO, is scheduled to present on January 10 at 9 am PST. The presentation can be accessed online at almirall.com/investors. Additionally, Almirall's executive team will conduct one-on-one investor meetings during the conference.
Almirall, a global biopharmaceutical company, is participating in the FACILITATE project, aimed at creating a framework for the access and reutilization of clinical trial participant data. This initiative, supported by 27 partners across 17 EU and non-EU States, seeks to ensure transparency and ethics in data handling. Almirall will leverage its expertise in privacy and pharmaceutical law to foster patient empowerment and improve the reuse of data in healthcare practices. The project, approved by IMI in 2021, will span four years and enhance the use of clinical trial data.
Almirall reports core net sales of €633.8 million for the first nine months of 2022, achieving a 5.3% year-on-year growth. The increase is primarily driven by the strong performance of its European Dermatology portfolio, with a notable 21% growth in dermatology sales. Despite a 19.2% decline in total EBITDA to €146.4 million due to increased R&D investments and product divestments, the company maintains a solid balance sheet with a 0.8x Net Debt to EBITDA ratio. Furthermore, the Marketing Authorization Application for Lebrikizumab has been accepted for evaluation by the European Medicines Agency.
Almirall has entered an exclusive licensing agreement with Simcere for the development and commercialization of SIM0278, an interleukin 2 mutant fusion protein for autoimmune diseases. The deal includes a $15 million upfront payment and potential milestone payments up to $492 million, along with tiered royalties on future sales. Almirall gains exclusive rights outside of Greater China, with Simcere retaining rights in that region. This collaboration aims to enhance Almirall's biologic pipeline and position in medical dermatology.
Twill, formerly known as Happify Health, has announced its transformation into a clinical-grade platform that enhances care experiences through its unique offering called Sequences™. These configurations combine digital therapeutics, care communities, and coaching, aimed at improving healthcare integration. Twill has secured contracts with major companies like Almirall, Biogen, and Elevance Health, focusing on medical conditions including mental health, multiple sclerosis, pregnancy, and psoriasis. The initiative aims to provide personalized, connected care while navigating a fragmented healthcare system.
Happify Health and Almirall have launched Claro, a digital wellness solution aimed at enhancing mental well-being for psoriasis patients in Spain, the U.K., and Italy. With 20-30% of moderate to severe psoriasis patients facing mental health challenges, Claro utilizes cognitive behavioral therapy, positive psychology, and mindfulness. This partnership highlights Almirall's commitment to providing comprehensive care for psoriasis, a condition affecting approximately 60 million people globally. The program is available in multiple languages and aims to improve treatment engagement and quality of life for users.